NASDAQ:OKYO - Nasdaq - GG00BMFG5F62 - Common Stock - Currency: USD
NASDAQ:OKYO (5/20/2025, 9:40:53 AM)
1.5988
0 (-0.08%)
The current stock price of OKYO is 1.5988 USD. In the past month the price increased by 36.5%. In the past year, price increased by 20.98%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.08 | 328.46B | ||
AMGN | AMGEN INC | 13.25 | 147.90B | ||
GILD | GILEAD SCIENCES INC | 13.71 | 132.13B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.02B | ||
REGN | REGENERON PHARMACEUTICALS | 13.46 | 64.42B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.73B | ||
ARGX | ARGENX SE - ADR | 97.7 | 35.02B | ||
ONC | BEIGENE LTD-ADR | 5.8 | 25.13B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.28B | ||
NTRA | NATERA INC | N/A | 20.78B | ||
BIIB | BIOGEN INC | 8.2 | 19.01B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.73B |
OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. The firm is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. Its research program is focused on a novel G Protein-Coupled Receptor (GPCR). The firm is developing OK-101, its lead preclinical product candidate, for the treatment of DED. OK-101 is focused on keratoconjunctivitis sicca, commonly referred to as DED, which is a multifactorial disease caused by an underlying inflammation resulting in the lack of lubrication and moisture in the surface of the eye. The firm also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. The company is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.
OKYO PHARMA LTD
Floor 4, 14/15 Conduit St
London GB
Employees: 8
Phone: 442074952379
The current stock price of OKYO is 1.5988 USD. The price decreased by -0.08% in the last trading session.
The exchange symbol of OKYO PHARMA LTD is OKYO and it is listed on the Nasdaq exchange.
OKYO stock is listed on the Nasdaq exchange.
7 analysts have analysed OKYO and the average price target is 7.14 USD. This implies a price increase of 346.58% is expected in the next year compared to the current price of 1.5988. Check the OKYO PHARMA LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.
OKYO PHARMA LTD (OKYO) has a market capitalization of 34.81M USD. This makes OKYO a Nano Cap stock.
OKYO PHARMA LTD (OKYO) currently has 8 employees.
OKYO PHARMA LTD (OKYO) has a support level at 1.37. Check the full technical report for a detailed analysis of OKYO support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
OKYO does not pay a dividend.
OKYO PHARMA LTD (OKYO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.18).
The outstanding short interest for OKYO PHARMA LTD (OKYO) is 1.16% of its float. Check the ownership tab for more information on the OKYO short interest.
ChartMill assigns a technical rating of 9 / 10 to OKYO. When comparing the yearly performance of all stocks, OKYO is one of the better performing stocks in the market, outperforming 93.15% of all stocks.
Over the last trailing twelve months OKYO reported a non-GAAP Earnings per Share(EPS) of -1.18. The EPS increased by 3.84% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -594.77% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 83% to OKYO. The Buy consensus is the average rating of analysts ratings from 7 analysts.